The in-vitro activities of four anticancer alkyllysophospholipids, ET-I8-OCH3 (edelfosine), hexadecylphosphocholine (miltefosine), ilmofosine and SRI 62-834, were determined with ED» values for Leishmania donovani and Trypanosoma cruzi amastigotes between 0.2 and 5.0 pM and for Trypanosoma brucei trypomastigotes between 7.0 and 50.8 pM. In BALB/c mice miltefosine and ilmofosine were the most active compounds with ED50 values of 2.9 and 14.5mg/kg x 5 doses against L. donovani and a suppressive effect on T. cruzi infections at 30 mg/kg x 5 doses.
Introduction
Leishmaniasis, South American trypanosomiasis (Chagas' disease) and human African trypanosomiasis (sleeping sickness) are diseases of tropical and sub-tropical regions, which are caused by closely related haemoflagellate protozoa belonging to the genera Leishmania and Trypanosoma. The recommended drugs for the treatment of these diseases include pentavalent antimonials, arsenicals and nitroheterocyclic compounds. None of these are adequate because of variable efficacy, toxicity, requirements for long courses of treatment, parenteral routes of administration, or a combination of these problems (Jernigan & Pearson 1993) .
In the search for new compounds for the treatment of leishmaniasis and trypanosomiasis a group of alkyllysophospholipids (ALPs) was identified with activity against Leishmania donovani, the causative agent of visceral leishmaniasis (Achterberg & Gercken, 1987a; Croft el al., 1987) . ALPs have been developed as anticancer drugs and have been the subject of extensive studies in tumour and leukaemia models during the past decade (Brachwitz & Vollgraf, 1995) . Several ALPs, including ilmofosine, miltefosine, edelfosine and SRI 62-834, reached clinical trial (Berdel, 1991) . Promising antiprotozoal activity has previously been reported for two of these compounds, hexadecylphosphocholine (miltefosine) and ilmofosine, against L. donovani in tissue culture and rodent models (Croft et al., 1987 (Croft et al., , 1993 Kuhlencord et al., 1992) . In this paper we describe a comparative study of the activity of all four anticancer ALPs against L. donovani, and report their novel activity against Trypanosoma cruzi, the causative organism of Chagas 1 disease, and Trypanosoma brucei, a member of the group of organisms that cause human African trypanosomiasis.
Materials and methods

Parasites
L. donovani strains MHOM/ET/67/L82, MHOM/IN/82/Nandi II and MHOM/IN/82/ Patna I were routinely maintained in golden hamsters (Wright's strain) by passage every 6 to 8 weeks. T. cruzi strains MHOM/BR/00/Y and MHOM/CL/00/Tulahuen were maintained by weekly passage in BALB/c mice (Tuck & Son Ltd, Hullbridge, UK) and in rat myoblast L6 cell cultures in Dulbecco's modified Eagle's medium with 10% heat inactivated fetal calf serum (hiFCS). T. brucei strain S427 ell 18 was maintained by passage in Sprague-Dawley rats (Tuck & Son Ltd) and by bi-weekly passage in HMI-18 medium with 10% hiFCS.
In-vitro studies L. donovani. Peritoneal macrophages were isolated from CD1 mice (Charles Rivers Ltd, Margate, UK) and maintained in Labtek 8-chamber slides (Nunc Inc., Naperville, IL, USA) in RPMI 1640 medium with 10% hiFCS at 37°C in a 5% CO 2 -air mixture. Amastigotes were isolated from the spleen of hamsters and used to infect the macrophage cultures. Infected cultures were maintained in medium containing test compounds in a three-fold dilution series, with quadruplicate cultures at each concentration, for 5 days (Croft et al., 1987) . Medium was replaced once with fresh medium containing drug during this period. After the 5 day exposure, slides were methanol fixed, Giemsa stained and the proportion of infected macrophages determined in each chamber. The 50% effective dose (EDjo) values were determined by linear regression analysis.
T. cruzi. Peritoneal macrophages were isolated and maintained by the procedure described above. Macrophages were infected with trypomastigotes derived from the overlay of the L6 myoblast cultures at a ratio of five parasites:one macrophage and maintained at 37°C in 5%CO 2 for 24 h. Infected macrophage cultures were then incubated with test compounds in a three-fold dilution series, with quadruplicate cultures at each concentration. After 3 days of drug exposure, slides were fixed, stained and examined as above and ED» values determined by linear regression analysis.
Trypomastigotes were harvested from the L6 myoblast monolayers cultures. 10 6 parasites/mL in Dulbecco's modified medium plus 20% hiFCS were incubated with ALPs in a ten fold dilution series from 10~3 to 10" 6 M in 96 well plates. Plates were maintained at 37'C or 4'C and the presence and motility of trypomastigotes in the cultures was monitored at 24 and 48 h using an inverted microscope.
T. brucei. Bloodstream form trypomastigotes, cultured in HMI-18 medium, were diluted to 10 ! cells/mL and 100/iL dispensed into wells of microtitre plate. Test compounds, diluted in HMI-18 medium, were added in another 100 nL volume to give the final drug concentration. Cultures were maintained at 37°C in 5% CO 2 for 48 h and the number of cells in each well counted on a ZM Coulter Counter with a 70 /im aperture. ED50 values were determined by linear regression analysis.
In-vivo studies L. donovani. Female BALB/c mice were infected intravenously with 10 7 amastigotes isolated from the spleen of an infected hamster and randomly sorted into groups of five.
One week after infection mice were dosed with the phospholipid analogues by the oral route and sodium stibogluconate subcutaneously once a day for 5 consecutive days. Three days after the completion of treatment the mice were killed, livers and spleens removed, weighed and impression smears prepared from a cut surface. Smears were methanol fixed and Giemsa stained. Drug activity was determined by comparing the number of amastigotes per 500 liver cells or spleen cells x organ weight (mg) in mice from treated and untreated groups. ED W values were calculated by linear regression analysis.
T. cruzi. Female BALB/c mice were infected intraperitoneally with 5-10 x 10 4 trypomastigotes isolated from a donor BALB/c mouse and randomly sorted into groups of five. Six days after infection, blood samples were taken from the tails of all animals were examined and only animals with parasites in 50 microscope fields (at 400 x magnification) were included in the experiment. Mice were then treated with phospholipid analogues and nifurtimox orally, once a day, for 5 consecutive days. Groups of mice were monitored daily for deaths and blood samples of all survivors were examined weekly for the presence of parasites. T. brucei. Bloodstream trypomastigotes were obtained from male Sprague-Dawley rats (Tuck Ltd) and purified by ion exchange chromatography on DE-52 cellulose. Trypomastigotes were diluted in PS buffer and 25 g female CDl mice (Charles Rivers Ltd) were infected with 5 x 10* parasites intraperitoneally. Twenty four hours after infection mice were dosed with ALPs orally for 4 consecutive days and melarsoprol for 1 day by the intraperitoneal route. The groups of mice were monitored daily and the number of survivors recorded.
(ET-18-OCH 3 ) was purchased from BACHEM Ltd (Saffron Waldon, UK) and, as edelfosine, was a gift from Medmark Pharma Gmbh (Grunwald, Germany). Hexadecylphosphocholine (HDPC) was purchased from Sigma (Poole, UK) and, as miltefosine, was a gift from Asta Werk Gmbh (Frankfurt, Germany). Both chemical and generic names of these two compounds are used in the text and Tables to differentiate the batches included in studies which probably varied in their purity and stability, l-hexadecylthio-2-methoxymethyl-rac-glycero-3-phosphocholine, ilmofosine (BM 41.440) was a gift from Dr Dieter Herrmann, Boehringer Mannheim Gmbh, Mannheim, Germany. SRI 62-834 was a gift from Dr 
Results
In-vitro studies
The results confirm previous reports of the activity of ilmofosine and hexadecylphosphocholine (HDPC) against intracellular L. donovani amastigotes (Croft et al., 1987 (Croft et al., , 1993 Kuhlencord et al., 1992) and show that two other ALPs, ET-I8-OCH3 and SRI 62-834 had similar activity with ED50 values in the range of 2 to 7 //M ( Table I) . The activities were similar against both the Ethiopian and Indian L. donovani strains. The ED50 of the standard drug sodium stibogluconate, was 4.1 /ig Sb v /mL. The four ALPs were also active against intracellular T. cruzi amastigotes in macrophages with ED50 values in the range of 0.1 to 1.5/iM (Table I ). In repeat tests ilmofosine and HDPC were consistently the most active compounds. The ED50 of the standard drug, nifurtimox, was 2.7 ^M. The ALPs were also tested against non-dividing T. cruzi trypomastigotes at 4°C and 37°C to evaluate their potential in the prevention of T. cruzi transmission through blood transfusion. All four compounds had MIC values of 10~3 M at both 4° and 37°C after 24 h whereas the MIC value for the standard drug, gentian violet, was 10~5M.
The ALPs were considerably less active against the extracellular bloodstream trypomastigote forms of T. brucei. Only ilmofosine had notable activity with ED50 values of 7.0 and 10.1 /iM in the two tests. These values are not comparable with activity of the standard drug pentamidine which had an ED50 value of 8 nM against both strains.
In-vivo studies
The activities of ilmofosine and miltefosine against L. donovani were similar to those already reported in the BALB/c mouse model following oral and subcutaneous administration (Kuhlencord et al., 1992; Croft et al., 1987 Croft et al., , 1993 . These ALPs were also equally active against a more recent Indian L. donovani isolate (Table II) In studies against established T. cruzi infections in BALB/c mice, ilmofosine, miltefosine and edelfosine had suppressive activity against T. cruzi Y strain and ilmofosine and miltefosine against T. cruzi Tulahuen strain at the top dose of 30 mg/kg x 5. SRI 62-834 was not effective against either strain at this dose. Mice treated at 15 mg/kg and below died at similar times to untreated mice, 12-16 days after infection. Although mice treated with 30 mg/kg of some APLs survived until the end of the experiment, 8 weeks after infection, parasites were detected in tail blood by microscopy in the weeks following treatment.
None of the ALPs showed activity against the acute infection of T. brucei S427 in mice. Mice treated at the top dose of 30 mg/kg x 4 died 7 days after infection at the same time as untreated controls.
Discussion
This paper extends the previous reports of the activity of ALPs against L. donovani (Achterberg & Gercken, 1987a; Croft et al., 1987 Croft et al., , 1993 Kuhlencord el al., 1992) and provides a comparative study of those ALPs that have been on clinical trial as anticancer drugs. We have also shown that these compounds have significant activity against intracellular T. cruzi amastigotes in vitro and some activity against the same parasite in vivo. All four ALPs studied had similar ranges of activity against L. donovani or T. cruzi amastigotes in vitro despite some differences in their structure: ET-I8-OCH3, ilmofosine and SRI 62-834 are alkylglycerophosphocholines whereas miltefosine is an alkylphosphocholine. Interestingly, the T. cruzi amastigotes were more sensitive to the ALPs than L. donovani amastigotes in vitro and had lower EDjo values despite incubation for 3 days compared with 5 days for the L. donovani test. At 4°C T. cruzi trypomastigotes were relatively insensitive to ALPs compared with sensitivity to gentian violet, the compound added to blood in South America to prevent the transmission of Chagas' disease by blood transfusion. Except for ilmofosine, extracellular T. brucei bloodstream form trypomastigotes were relatively insensitive to the ALPs possibly because of differences in membrane structure and lipid biosynthesis in African trypanosomes compared with those of Leishmania and T. cruzi (Haughan & Goad, 1991) .
Although all four ALPs tested have in-vivo activities against tumour cells (Berdel, 1991; Brachwitz & Vollgraf, 1995) , in the BALB/c mouse models only ilmofosine and miltefosine showed promising activity against L. donovani and T. cruzi. The basis for this difference is not clear, but could be due to variation in pharmacological properties in the mouse model. In a previous study alkylphosphocholines were active against L. donovani both in vitro and in vivo whereas an alkylphosphoethanolamine was active in vitro but inactive in vivo (Croft et al., 1987) .
The anticancer activity of ALPs appears to lie in their effects on phospholipid biosynthesis, protein kinase C, phospholipase C, cell invasion and macrophage activation (Brachwitz & Vollgraf, 1995) . Although the mechanisms of action against protozoa have not been determied, studies by Achterberg & Gercken (19876) suggested that acyltransferases, lysophospholipase D and phosphohydrolase in Leishmania are targets. The lysophospholipid salvage pathway in T. brucei would appear to be less "Oral administration, once/day for 5 days. *Miltefosine is the generic name for hexadecylphophocholine (HDPC) and edelfosine is the generic name for ET-I8-OCH3. sensitive to these drugs (Haughan & Goad, 1991) . A non-specific membrane activity at high concentrations is suggested by the low activity of the ALPs against T. cruzi trypomastigotes at 4°C. The role of ALPs in macrophage activation must also be considered; one ALP, the alkyl-linked lipoidal amine CP-46,665, has been shown to increase intracellular killing of Leishmania and enhance the antileishmanial activity of the pentavalent antimonial drug, meglumine antimonate, in mice (Adinolfi & Bonventre, 1985) .
ALPs are novel antiprotozoal drugs. Their activity against L. donovani and T. cruzi in rodent models following oral administration indicates their potential as drugs for the treatment of leishmaniasis and South American trypanosomiases. The development of ALPs as anticancer agents ensures that there will be data on the pharmacology, toxicology and tolerance of these compounds in humans, factors which are of importance for reducing the cost of development of drugs for tropical parasitic diseases.
